دورية أكاديمية

The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).

التفاصيل البيبلوغرافية
العنوان: The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
المؤلفون: Hongqian, Guo, Subudhi, Sumit Kumar, Han, Weiqing, Liao, Chih-Yi, Zhang, Shun, Dai, Tao, Peng, Peng, Sun, Caixia, Wang, Hui, Hennessy, Katie, Fu, Ximei, Yu, Yingying, Wu, Yingtong, Li, Qing, Xu, Ruolan, Huang, Peng, Neo, Levin, Wu, Frank, Fan, Jean, Piha-Paul, Sarina A.
المصدر: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p133-133, 235p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2024.42.4_suppl.133